According to a WHO report published in November 2017, CBD is safe and well tolerated in humans and animals. And is not associated with any negative public health effects.
A World Health Organization report has found no adverse health outcomes but rather several medical applications for CBD and CBD oil.
Experts further stated that CBD is not psychoactive and does not induce physical dependence. Further that CBD is "not associated with abuse potential." The WHO also wrote that, unlike THC, people aren't getting high off of CBD, either.
"To date, there is no evidence of the recreational use of CBD or any public health-related problems associated with the use of pure CBD," they wrote. In fact, evidence suggests that CBD mitigates the effects of THC. The authors pointed out that research has officially confirmed some positive effects of the chemical, however.
CBD as an effective treatment
The WHO determined that CBD has "been demonstrated as an effective treatment for epilepsy" in adults, children, and animals and that there's "preliminary evidence" that CBD could be useful in treating Alzheimer's disease, cancer, psychosis, Parkinson's disease, and other serious conditions.
In acknowledgment of these kinds of discoveries in recent years, the report continued, "Several countries have modified their national controls to accommodate CBD as a medicinal product."
War against CBD in the USA
But the U.S. isn't one of them. As a cannabis component, CBD remains classified as a Schedule I controlled substance, meaning it has a "high potential for abuse". Nevertheless, the "unsanctioned medical use" of CBD is fairly common, experts found.
For many CBD users in the U.S., the substance's mostly unsanctioned and illegal state creates problems, especially as a wave of online and store-bought CBD oils and extracts have allowed patients to take the treatment process.
As the cannabis reform nonprofit NORML reported, the WHO is currently considering changing CBD's place in its own drug scheduling code. In September, NORML submitted written testimony to the U.S. Food and Drug Administration (FDA) opposing the enactment of international restrictions on access to CBD.
